64 related articles for article (PubMed ID: 6130314)
1. Ketanserin: a selective antagonist of 5-HT2 serotoninergic receptors.
Van Nueten JM; Leysen JE; Schuurkes JA; Vanhoutte PM
Lancet; 1983 Feb; 1(8319):297-8. PubMed ID: 6130314
[No Abstract] [Full Text] [Related]
2. Assessment of affinity and dissociation ability of a newly synthesized 5-HT2 antagonist, AT-1015: comparison with other 5-HT2 antagonists.
Rashid M; Watanabe M; Nakazawa M; Nakamura T; Hattori K; Nagatom T
Jpn J Pharmacol; 2001 Nov; 87(3):189-94. PubMed ID: 11885967
[TBL] [Abstract][Full Text] [Related]
3. Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.
Leysen JE; Awouters F; Kennis L; Laduron PM; Vandenberk J; Janssen PA
Life Sci; 1981 Mar; 28(9):1015-22. PubMed ID: 6261070
[No Abstract] [Full Text] [Related]
4. CGS 18102A, a benzopyranopyridine anxiolytic with 5-HT1 agonist and 5-HT2 antagonist properties.
Sills MA; Bennett DA; Lovell RA; Liebman JM; Wood PL; Glaeser BS; Williams M; Hutchison AJ
Prog Clin Biol Res; 1990; 361():469-75. PubMed ID: 1981265
[No Abstract] [Full Text] [Related]
5. Central serotonin antagonist activity of ketanserin.
Fuller RW; Snoddy HD
Res Commun Chem Pathol Pharmacol; 1984 Oct; 46(1):151-4. PubMed ID: 6505385
[TBL] [Abstract][Full Text] [Related]
6. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat.
Lucki I; Nobler MS; Frazer A
J Pharmacol Exp Ther; 1984 Jan; 228(1):133-9. PubMed ID: 6694097
[TBL] [Abstract][Full Text] [Related]
7. 5-HT2-receptor antagonists: alpha 1- vs. 5-HT2-receptor blocking properties in blood vessels.
Cohen ML; Schenck KW; Kurz KD
J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S25-9. PubMed ID: 2459510
[TBL] [Abstract][Full Text] [Related]
8. Vascular activity of ketanserin (R 41 468), a selective 5-HT2 receptor antagonist.
Van Nueten JM; Xhonneux R; Vanhoutte PM; Janssen PA
Arch Int Pharmacodyn Ther; 1981 Apr; 250(2):328-9. PubMed ID: 7271395
[No Abstract] [Full Text] [Related]
9. 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors.
Lyon RA; Davis KH; Titeler M
Mol Pharmacol; 1987 Feb; 31(2):194-9. PubMed ID: 3543649
[TBL] [Abstract][Full Text] [Related]
10. Regional distribution of serotonin-2 receptor binding sites in the brain and effects of neuronal lesions.
Leysen JE; Geerts R; Gommeren W; Verwimp M; Van Gompel P
Arch Int Pharmacodyn Ther; 1982 Apr; 256(2):301-5. PubMed ID: 7103617
[No Abstract] [Full Text] [Related]
11. Peripheral 5-HT2-like receptors. Can they be classified with the available antagonists?
Leff P; Martin GR
Br J Pharmacol; 1986 Jul; 88(3):585-93. PubMed ID: 2943354
[TBL] [Abstract][Full Text] [Related]
12. Neurochemical and behavioral evidence that quipazine-ketanserin discrimination is mediated by serotonin2A receptor.
Smith RL; Barrett RJ; Sanders-Bush E
J Pharmacol Exp Ther; 1995 Nov; 275(2):1050-7. PubMed ID: 7473132
[TBL] [Abstract][Full Text] [Related]
13. [In vivo study of central serotoninergic receptors in man using positron tomography].
Baron JC; Samson Y; Comar D; Crouzel C; Deniker P; Agid Y
Rev Neurol (Paris); 1985; 141(8-9):537-45. PubMed ID: 2935920
[TBL] [Abstract][Full Text] [Related]
14. Three distinct subtypes of serotonergic receptors mediate the triphasic blood pressure response to serotonin in rats.
Kalkman HO; Engel G; Hoyer D
J Hypertens Suppl; 1984 Dec; 2(3):S143-5. PubMed ID: 6599662
[TBL] [Abstract][Full Text] [Related]
15. Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain.
Appel NM; Mitchell WM; Garlick RK; Glennon RA; Teitler M; De Souza EB
J Pharmacol Exp Ther; 1990 Nov; 255(2):843-57. PubMed ID: 2243353
[TBL] [Abstract][Full Text] [Related]
16. Ketanserin: a selective serotonin antagonist.
Lancet; 1982 Oct; 2(8303):859. PubMed ID: 6126719
[No Abstract] [Full Text] [Related]
17. Is ketanserin a D receptor antagonist?
Lancet; 1983 Mar; 1(8326 Pt 1):703-4. PubMed ID: 6132056
[No Abstract] [Full Text] [Related]
18. Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats.
Kleven MS; Assié MB; Koek W
J Pharmacol Exp Ther; 1997 Aug; 282(2):747-59. PubMed ID: 9262338
[TBL] [Abstract][Full Text] [Related]
19. Ketanserin, a new selective 5-HT2 receptor blocking agent, inhibits the antidiuretic effect of 5-hydroxytryptamine (5-HT) in Wistar rats.
Cantalamessa F; de Caro G; Massi M; Micossi LG
Arch Int Pharmacodyn Ther; 1983 Feb; 261(2):302-7. PubMed ID: 6838287
[No Abstract] [Full Text] [Related]
20. Tryptaminergic receptors in the bovine pulmonary vasculature: effects of ketanserin.
Ogunbiyi PO; Eyre P
Res Commun Chem Pathol Pharmacol; 1984 Apr; 44(1):31-55. PubMed ID: 6328601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
